0
0
1/2/24 at 10:32am
Organization
CNBC
Author
Annika Kim Constantino
35 words
0
Comments
The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot.
You are the first to view
https://www.cnbc.com/2024/01/02/moderna-stock-jumps-after-oppenheimer-upgrade-on-pipeline-potential.html
Create an account
or login to join the discussion